Patents by Inventor Christian Wiesmann

Christian Wiesmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VEGF ANTIBODIES
    Publication number: 20130315918
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 28, 2013
    Applicant: Genentech, Inc.
    Inventors: GERMAINE FUH, HANS-PETER GERBER, WEI-CHING LIANG, FREDERIC FELLOUSE, SACHDEV S. SIDHU, CHRISTIAN WIESMANN
  • ANTI-VEGF ANTIBODIES
    Publication number: 20130266581
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 25, 2013
    Publication date: October 10, 2013
    Inventors: Germaine FUH, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Anti-VEGF antibodies
    Patent number: 8512699
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: August 20, 2013
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8497094
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 30, 2013
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Anti-VEGF antibodies
    Patent number: 8492527
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: July 23, 2013
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Crystal structures of neuropilin fragments and neuropilin-antibody complexes
    Patent number: 8466264
    Abstract: The invention provides crystal structures of neuropilin 1 (Nrp1) and neuropilin 2 (Nrp2) fragments alone and in complex with anti-neuropilin antibodies, and method for their use. The invention further provides anti-Nrp antibodies and methods for their therapeutic applications.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: June 18, 2013
    Assignee: Genentech, Inc.
    Inventors: Brent A. Appleton, Christian Wiesmann, Yan Wu
  • Phosphoinositide 3-kinase inhibitor compounds and methods of use
    Patent number: 8450315
    Abstract: Methods of using compounds of Formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 28, 2013
    Assignees: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Georgette Castanedo, Richard Goldsmith, Janet Gunzner, Tim Heffron, Kimberly Malesky, Simon Mathieu, Alan Olivero, Daniel P. Sutherlin, Vickie Tsui, Shumei Wang, Christian Wiesmann, Bing-Yan Zhu, Jennafer Dotson, Adrian Folkes, Stephen Shuttleworth, Sally Oxenford, Tim Hancox, Tracy Bayliss
  • Anti-FGFR3 antibodies and methods using same
    Patent number: 8410250
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: April 2, 2013
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20130052685
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 20, 2012
    Publication date: February 28, 2013
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • ANTI-VEGF ANTIBODIES
    Publication number: 20120322982
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Application
    Filed: December 22, 2011
    Publication date: December 20, 2012
    Applicant: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • CRYSTAL STRUCTURES AND METHODS USING SAME
    Publication number: 20120321606
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of FGFR3 function, and the identification and uses of said modulators.
    Type: Application
    Filed: August 10, 2012
    Publication date: December 20, 2012
    Applicant: Genentech, Inc.
    Inventor: Christian Wiesmann
  • CRYSTAL STRUCTURES OF NEUROPILIN FRAGMENTS AND NEUROPILIN-ANTIBODY COMPLEXES
    Publication number: 20120322989
    Abstract: The invention provides crystal structures of neuropilin 1 (Nrp1) and neuropilin 2 (Nrp2) fragments alone and in complex with anti-neuropilin antibodies, and method for their use. The invention further provides anti-Nrp antibodies and methods for their therapeutic applications.
    Type: Application
    Filed: July 3, 2012
    Publication date: December 20, 2012
    Inventors: Brent A. APPLETON, Christian Wiesmann, Yan Wu
  • Anti-pan neuropilin antibody and binding fragments thereof
    Patent number: 8318163
    Abstract: The invention provides crystal structures of neuropilin 1 (Nrp1) and neuropilin 2 (Nrp2) fragments alone and in complex with anti-neuropilin antibodies, and method for their use. The invention further provides anti-Nrp antibodies and methods for their therapeutic applications.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: November 27, 2012
    Assignee: Genentech, Inc.
    Inventors: Brent A. Appleton, Christian Wiesmann, Yan Wu
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8268310
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: September 18, 2012
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • HGF ? chain variants
    Patent number: 8110377
    Abstract: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.
    Type: Grant
    Filed: April 27, 2010
    Date of Patent: February 7, 2012
    Assignee: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Christian Wiesmann
  • Anti-VEGF antibodies
    Patent number: 8101177
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naive libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: January 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • Anti-VEGF antibodies
    Patent number: 8092797
    Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: January 10, 2012
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
  • PREVENTION AND TREATMENT OF COMPLEMENT-ASSOCIATED EYE CONDITIONS
    Publication number: 20110282034
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Application
    Filed: July 22, 2011
    Publication date: November 17, 2011
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, JR., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Prevention and treatment of complement-associated eye conditions
    Patent number: 8007791
    Abstract: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Philip Hass, Yin Jianping, Kenneth Katschke, Jr., Micah Steffek, Christian Wiesmann, Menno Van Lookeren Campagne
  • Co-crystal structure of factor D and anti-factor D antibody
    Publication number: 20110165648
    Abstract: The present invention is directed towards the co-crystal structure of Factor D and an anti-Factor D antibody or an antigen binding fragment thereof.
    Type: Application
    Filed: November 3, 2010
    Publication date: July 7, 2011
    Inventors: Menno Van Lookeren Campagne, Christian Wiesmann